Keyphrases
United States
100%
State-based
100%
Chemotherapy
100%
Bevacizumab
100%
Metastatic Colorectal Cancer (mCRC)
100%
Cost-effectiveness Analysis
100%
Quality-adjusted Life Years
66%
Cost-effectiveness
22%
Standard of Care
22%
Incremental Cost-effectiveness Ratio
22%
Leucovorin
22%
Fluorouracil
22%
Health Outcomes
11%
Randomized Trial
11%
Sensitivity Analysis
11%
Overall Survival
11%
Modeling Analysis
11%
Median Overall Survival
11%
First-line Therapy
11%
Markov Model
11%
First-line Regimen
11%
Irinotecan
11%
Incremental Cost
11%
Previously Untreated
11%
Second-line Treatment
11%
Colorectal Cancer Prevention
11%
Payers
11%
Probabilistic Sensitivity Analysis
11%
Oxaliplatin
11%
Fluoropyrimidine-based Chemotherapy
11%
Model Robustness
11%
Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Bevacizumab
100%
Metastatic Colorectal Cancer
100%
Quality Adjusted Life Year
54%
Health Care Cost
45%
Fluorouracil
27%
Overall Survival
18%
Folinic Acid
18%
Health Outcomes
9%
Cancer Therapy
9%
Irinotecan
9%
Oxaliplatin
9%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Bevacizumab
100%
Metastatic Colorectal Cancer
100%
Fluorouracil
27%
Overall Survival
18%
Folinic Acid
18%
Irinotecan
9%
Oxaliplatin
9%